Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Eptifibatide
Drug ID BADD_D00792
Description Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Indications and Usage For treatment of myocardial infarction and acute coronary syndrome.
Marketing Status approved; investigational
ATC Code B01AC16
DrugBank ID DB00063
KEGG ID D06888
MeSH ID D000077542
PubChem ID 448812
TTD Drug ID D09ZIO
NDC Product Code 36974-0068; 52958-001; 25021-409; 52958-040; 67457-630; 70860-303; 14403-0007; 67457-631; 70860-305; 72078-027; 0338-9558; 70436-026; 52958-402; 70436-162; 41524-0002; 55150-220; 67457-629; 70121-1002; 72078-025; 32861-0002; 16729-259; 55150-218; 55150-219; 70121-1003; 70436-027; 70436-163; 52958-128; 16729-260; 72078-026; 25021-408
UNII NA8320J834
Synonyms Eptifibatide | Epifibratide | Epifibatide | 7H-Pyrrolo(2,1-g)(1,2,5,8,11,14,17,20)dithiahexaazacyclotricosine-17-acetic acid, 3-(aminocarbonyl)-11-(4-((aminoiminomethyl)amino)butyl)docosahydro-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-, (3R,11S,17S,20S,25aS)- | Integrilin | Integrelin
Chemical Information
Molecular Formula C35H49N11O9S2
CAS Registry Number 188627-80-7
SMILES C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC (=O)O)CCCCN=C(N)N)C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
Haemoglobin13.01.05.018--Not Available
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.0040.000123%Not Available
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
Haemorrhagic stroke24.07.04.014; 17.08.01.011--Not Available
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypotension24.06.03.0020.000206%
Hypoxia22.02.02.0030.000123%
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Injury12.01.08.004--Not Available
Liver disorder09.01.08.001--Not Available
Lymphoma16.20.01.001; 01.12.01.001--Not Available
Myocardial infarction02.02.02.007; 24.04.04.009--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Non-Hodgkin's lymphoma16.35.01.001; 01.17.01.001--Not Available
Pain08.01.08.004--
Pericardial effusion02.06.01.002--
Petechiae23.06.01.003; 01.01.03.002; 24.07.06.0040.000082%Not Available
Phlebitis24.12.03.004; 12.02.01.002--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pulmonary alveolar haemorrhage24.07.01.015; 22.01.02.0050.000082%Not Available
Pulmonary haemorrhage24.07.01.016; 22.12.01.0090.000304%
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene